---
layout: default
title: Sevoflurane
parent: Model Prediction Only (L5)
nav_order: 764
evidence_level: L5
indication_count: 10
---

# Sevoflurane
{: .fs-9 }

Evidence Level: **L5** | Predicted Indications: **10** 
{: .fs-6 .fw-300 }

---

## Table of Contents
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## Pharmacist Assessment Report

</div>

# Sevoflurane: From General Anesthesia to Prinzmetal Angina

## One-Sentence Summary

> Sevoflurane is an inhalational general anesthetic, used for induction and maintenance of general anesthesia.
> The TxGNN model predicts it may be effective for **Prinzmetal Angina**,
> but currently **no clinical trials** and **no supporting literature** exist for this specific indication, and the mechanistic linkage is considered weak.

---

## Quick Overview

| Item | Content |
|------|------|
| Original Indication | General Anesthesia (inhalational agent; detailed MOA/label indication data not yet available) |
| Predicted New Indication | Prinzmetal Angina |
| TxGNN Prediction Score | 99.78% |
| Evidence Level | L5 |
| Taiwan Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DG002, High severity data gap pending DrugBank confirmation). Based on the available pharmacological description, Sevoflurane is an inhalational general anesthetic that acts primarily on central nervous system GABA_A/NMDA receptors, and secondarily suppresses myocardial contractility and vascular tone.

There is indirect physiological literature on anesthetic-induced myocardial "preconditioning" (a cardioprotective effect against ischemia), which may partially explain why the TxGNN knowledge graph links Sevoflurane to a cardiovascular disease node. However, Prinzmetal angina's core pathology — coronary artery vasospasm from smooth muscle hyperreactivity — has no established direct molecular connection to Sevoflurane's known receptor pharmacology.

**This is likely a knowledge-graph co-occurrence signal rather than a mechanism-supported prediction.** The high TxGNN score (99.78%) reflects statistical proximity between "anesthetic agents" and "cardiovascular" nodes in the graph, not validated pharmacological plausibility. No clinical or preclinical evidence currently supports therapeutic use of Sevoflurane in Prinzmetal angina.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Taiwan Market Information

Sevoflurane is currently **not marketed** in Taiwan under this dataset (0 registered licenses). No product registration or approved-indication data is available to summarize.

---

## Safety Considerations

**Drug Interactions**
A total of **146 drug-drug interactions** were identified in the DDI database. Notable **Major**-level interactions include:

| Interacting Drug | Severity | Source |
|---|---|---|
| Epinephrine | Major | DDInter |
| Cisapride | Major | DDInter |
| Dolasetron | Major | DDInter |

Additional **Moderate**-level interactions were identified with agents including Famotidine, Loperamide, Morphine, Clarithromycin, Levofloxacin, Ondansetron, Palonosetron, Exenatide, and several laxative/bowel-prep agents (Bisacodyl, Lactulose, Lactitol, Polyethylene glycol, Sodium sulfate, Castor oil).

Key warnings and contraindications data are not yet available (blocking data gap DG001 — TFDA label PDF not yet retrieved/parsed).

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The predicted indication (Prinzmetal angina) has no supporting clinical trials or literature, and the internal repurposing rationale itself flags the mechanistic link as indirect/weak — likely a knowledge-graph artifact rather than a genuine pharmacological signal. The drug is also not currently marketed in Taiwan, and core safety data (label warnings, contraindications, and MOA) remain unresolved data gaps.

**To proceed, the following is needed:**
- TFDA label (warnings/contraindications) — currently a **Blocking** data gap (DG001)
- Confirmed mechanism of action from DrugBank — currently a **High** severity data gap (DG002)
- Preclinical or mechanistic studies specifically linking Sevoflurane to coronary vasospasm/Prinzmetal angina pathophysiology
- If pursued further, initial hypothesis-generating research (in vitro/animal models) before any clinical evidence can be considered
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

